Ellen McErlean

4.0k citations

29 papers · 2.1k · 2 hit papers · h-index 16

Impact in

Cardiology and Cardiovascular Medicine top 2%
- Acute Myocardial Infarction Research
- Cardiomyopathy and Myosin Studies
- Cardiovascular Function and Risk Factors
Endocrinology, Diabetes and Metabolism top 5%
- Diabetes, Cardiovascular Risks, and Lipoproteins

Papers in

Cardiology and Cardiovascular Medicine 20
- Acute Myocardial Infarction Research 7
- Antiplatelet Therapy and Cardiovascular Diseases 4
- Cardiovascular Function and Risk Factors 4
Surgery 17
- Lipoproteins and Cardiovascular Health 9
- Coronary Interventions and Diagnostics 4

Co-authors: Steven E. Nissen (17 shared papers)Frederick Van Lente (5 shared papers)Eric J. Topol (4 shared papers)Ronnier J. Aviles (2 shared papers)Vijay Nambi (2 shared papers)Marie‐Luise Brennan (2 shared papers)Stanley L. Hazen (2 shared papers)Michael Pepoy (2 shared papers)
Journals: American Heart Journal (4 papers)Circulation (3 papers)Journal of the American College of Cardiology (3 papers)The Journal of Cardiovascular Nursing (3 papers)JAMA (2 papers)
Partner nations: United States Australia Netherlands

In The Last Decade

Ellen McErlean

28 papers receiving 2.0k citations

Ellen McErlean's Hit Papers

align trajectories log scale

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy 2022 · 183 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Journal of the American College of Cardiology
2003 New England Journal of Medicine

Peers

Countries citing papers authored by Ellen McErlean

Since Specialization

Citations

This map shows the geographic impact of Ellen McErlean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen McErlean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen McErlean more than expected).

Fields of papers citing papers by Ellen McErlean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen McErlean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen McErlean. The network helps show where Ellen McErlean may publish in the future.

Co-authors

The 25 scholars most cited alongside Ellen McErlean, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ellen McErlean Line = papers co-authored together Ellen McErlean links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Prognostic Value of Myeloperoxidase in Patients with Chest Pain New England Journal of Medicine ·Marie‐Luise Brennan, Marc S. Penn, Frederick Van Lente, Vijay Nambi, Mehdi H. Shishehbor, Ronnier J. Aviles, Marlene Goormastic, Michael Pepoy, Ellen McErlean, Eric J. Topol, Steven E. Nissen, Stanley L. Hazen Hit paper breakdown →	2003	796
2	Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol JAMA ·Stephen J. Nicholls, H. Bryan Brewer, John J.P. Kastelein, Kathryn A. Krueger, Ming-Dauh Wang, Mingyuan Shao, Bo Hu, Ellen McErlean, Steven E. Nissen	2011	299
3	Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy Journal of the American College of Cardiology ·Milind Y. Desai, Anjali Owens, Jeffrey B. Geske, Kathy Wolski, Srihari S. Naidu, Nicholas G. Smedira, Paul Cremer, Hartzell V. Schaff, Ellen McErlean, Christina Sewell, Wanying Li, Lulu Ren Sterling, Kathy Lampl, Jay M. Edelberg, Amy J. Sehnert, Steven E. Nissen Hit paper breakdown →	2022	183
4	Effects of a Potent and Selective PPAR-α Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia JAMA ·Steven E. Nissen, Stephen J. Nicholls, Kathy Wolski, Daniel C. Howey, Ellen McErlean, Ming-Dauh Wang, Elisa Gómez, John M. Russo	2007	95
5	Prognostic Value of Myeloperoxidase in Patients With Chest Pain Obstetrical & Gynecological Survey ·Marie‐Luise Brennan, Marc S. Penn, Frederick Van Lente, Vijay Nambi, Mehdi H. Shishenbor, Ronnier J. Aviles, Marlene Goormastic, Michael Pepoy, Ellen McErlean, Eric J. Topol, Steven E. Nissen, Stanley L. Hazen	2004	91
6	Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study Journal of the American College of Cardiology ·Frederick Van Lente, Ellen McErlean, Sue A. Deluca, W. Franklin Peacock, J. Sunil Rao, Steven E. Nissen	1999	85
7	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease JAMA Cardiology ·Rishi Puri, Steven E. Nissen, Benoît J. Arsenault, Julie St. John, Jeffrey S. Riesmeyer, Giacomo Ruotolo, Ellen McErlean, Venu Menon, Leslie Cho, Kathy Wolski, A. Michael Lincoff, Stephen J. Nicholls	2020	85
8	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial American Heart Journal ·Stephen J. Nicholls, A. Michael Lincoff, Philip J. Barter, H Bryan Brewer, Keith A.A. Fox, C. Michael Gibson, Christopher M. Grainger, Venugopal Menon, Gilles Montalescot, Daniel J. Rader, Alan R. Tall, Ellen McErlean, Jeffrey Riesmeyer, Burkhard Vangerow, Giacomo Ruotolo, Govinda J. Weerakkody, Steven E. Nissen	2015	67
9	Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks Circulation ·Milind Y. Desai, Anjali Owens, Jeffrey B. Geske, Kathy Wolski, Sara Saberi, Andrew Wang, Mark V. Sherrid, Paul Cremer, Srihari S. Naidu, Nicholas G. Smedira, Hartzell V. Schaff, Ellen McErlean, Christina Sewell, Aarthi Balasubramanyam, Kathy Lampl, Amy J. Sehnert, Steven E. Nissen	2022	53
10	Differences between men and women in anxiety early after acute myocardial infarction American Journal of Critical Care ·Kyoung‐Ah Kim, D K Moser, Bonnie J. Garvin, Bárbara Riegel, Lynn V. Doering, Rosemary A. Jadack, S. McKinley, Armin Schueler, L Underman, Ellen McErlean	2000	47
11	Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy American Heart Journal ·Milind Y. Desai, Kathy Wolski, Anjali Owens, Srihari S. Naidu, Jeffrey B. Geske, Nicholas G. Smedira, Hartzell V. Schaff, Kathy Lampl, Ellen McErlean, Christina Sewell, David Zhang, Jay M. Edelberg, Amy J. Sehnert, Steven E. Nissen	2021	38
12	Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers Journal of the American College of Cardiology ·Luke J. Laffin, Dennis Bruemmer, M. Gómez García, Danielle M. Brennan, Ellen McErlean, Douglas S. Jacoby, Erin D. Michos, Paul M. Ridker, Tracy Y. Wang, Karol E. Watson, Howard G. Hutchinson, Steven E. Nissen	2022	37
13	Comparison of troponin T versus creatine kinase-MB in suspected acute coronary syndromes The American Journal of Cardiology ·Ellen McErlean, Sue A. Deluca, Frederick Van Lente, Franklin Peacock, J. Sunil Rao, Craig Balog, Steven E. Nissen	2000	33
14	Peroxisome proliferator–activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study American Heart Journal ·Deepak L. Bhatt, Derek P. Chew, Cindy L. Grines, Debabrata Mukherjee, Massoud A. Leesar, Ian C. Gilchrist, John Corbelli, James C. Blankenship, Avichai Eres, Steven R. Steinhubl, Walter A. Tan, Jon R. Resar, Amjad AlMahameed, Ahmed Abdel‐Latif, W.H. Wilson Tang, Danielle M. Brennan, Ellen McErlean, Stanley L. Hazen, Eric J. Topol	2007	30
15	ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease JAMA Cardiology ·Steven E. Nissen, Sreekumar Pillai, Stephen J. Nicholls, Kathy Wolski, Jeffrey S. Riesmeyer, Govinda J. Weerakkody, Wendra M. Foster, Ellen McErlean, Lin Li, Pallav Bhatnagar, Giacomo Ruotolo, A. Michael Lincoff	2018	27
16	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial BMJ Open Diabetes Research & Care ·Venu Menon, Anirudh Kumar, Divyang Patel, Julie St. John, Jeffrey Riesmeyer, Govinda J. Weerakkody, Giacomo Ruotolo, Kathy Wolski, Ellen McErlean, Paul Cremer, Stephen J. Nicholls, A. Michael Lincoff, Steven E. Nissen	2020	19
17	What Is the Metabolic Syndrome? The Journal of Cardiovascular Nursing ·Marilyn Borgman, Ellen McErlean	2006	14
18	Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro–B-type natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) substudy American Heart Journal ·W.H. Wilson Tang, Steven R. Steinhubl, Frederick Van Lente, Danielle M. Brennan, Ellen McErlean, Anjli Maroo, Gary S. Francis, Eric J. Topol	2006	11
19	Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy Journal of the American Heart Association ·Venu Menon, Anirudh Kumar, Divyang Patel, Julie St. John, Kathy Wolski, Ellen McErlean, Jeffrey S. Riesmeyer, Govinda J. Weerakkody, Giacomo Ruotolo, Paul Cremer, Stephen J. Nicholls, A. Michael Lincoff, Steven E. Nissen	2019	11
20	Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial Diabetes and Vascular Disease Research ·Anirudh Kumar, Divyang Patel, Kathy Wolski, A. Michael Lincoff, Sangeeta R. Kashyap, Giacomo Ruotolo, Ellen McErlean, Govinda J. Weerakkody, Jeffrey S. Riesmeyer, Stephen J. Nicholls, Steven E. Nissen, Venu Menon	2019	10

About Ellen McErlean

Ellen McErlean is a scholar working on Cardiology and Cardiovascular Medicine, Surgery, Endocrinology, Diabetes and Metabolism, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 29 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (9 papers), Acute Myocardial Infarction Research (7 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers), Cancer, Lipids, and Metabolism (4 papers), Antiplatelet Therapy and Cardiovascular Diseases (4 papers), Cardiovascular Function and Risk Factors (4 papers), Coronary Interventions and Diagnostics (4 papers) and Cardiac Imaging and Diagnostics (4 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (919 citations), Endocrinology, Diabetes and Metabolism (417 citations), Immunology (465 citations), Surgery (712 citations) and Cancer Research (169 citations). Ellen McErlean has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Steven E. Nissen, Frederick Van Lente, Eric J. Topol, Ronnier J. Aviles, Vijay Nambi, Marie‐Luise Brennan, Stanley L. Hazen, Michael Pepoy, Marlene Goormastic and Marc S. Penn. Their work appears in journals such as American Heart Journal, Circulation, Journal of the American College of Cardiology, The Journal of Cardiovascular Nursing and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Ellen McErlean

Impact in

Papers in i

In The Last Decade

Ellen McErlean

Ellen McErlean's Hit Papers

Peers

Countries citing papers authored by Ellen McErlean

Fields of papers citing papers by Ellen McErlean

All Works

About Ellen McErlean

Explore authors with similar magnitude of impact

Papers in